← New England News
Health

🧬 Two Massachusetts biotech firms announce major job cutsFractyl Health plans 45% reduction while EyePoint will eliminate 105 jobs 👇

Two Massachusetts biotechnology companies are cutting roughly half their workforces as they narrow their drug-development programs, adding to recent employment losses in one of the state's major industries.

Burlington-based Fractyl Health announced a 45% workforce reduction as it shifts resources toward Revita, an experimental procedure intended to help patients maintain weight loss after stopping GLP-1 drugs. Fractyl reported 100 full-time employees as of March, meaning the reduction would represent about 45 jobs if staffing remained near that level. Most of the cuts are expected to be completed by November.

Fractyl is also ending development of its Rejuva gene-therapy program for type 2 diabetes. The company instead plans to focus on Revita and expects to seek FDA authorization to market the treatment near the end of 2026.

Watertown-based EyePoint Pharmaceuticals plans to eliminate 105 positions, according to a notice filed with Massachusetts. The company announced its restructuring after its experimental treatment DURAVYU failed to achieve the primary goal of a major study involving patients with wet age-related macular degeneration. EyePoint will end late-stage studies for that condition and focus on testing DURAVYU for diabetic macular edema, another condition that can cause vision loss.

EyePoint said the restructuring is expected to save approximately $30 million annually. The company has operations in Watertown and a manufacturing facility in Northbridge.

The cuts come during an uneven period for Massachusetts biotech. Industry group MassBio reported that investment improved during the first half of 2026, but biotech employment fell by approximately 3,600 jobs in 2025, the first annual decline in more than two decades of tracking.

Community Discussion
💬 Do these latest job cuts suggest Massachusetts biotech employment will remain under pressure even as investment begins to recover?